Compare VRTX & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | SBUX |
|---|---|---|
| Founded | 1989 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Restaurants |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4B | 120.0B |
| IPO Year | 2006 | 1994 |
| Metric | VRTX | SBUX |
|---|---|---|
| Price | $478.38 | $105.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 29 |
| Target Price | ★ $539.69 | $104.39 |
| AVG Volume (30 Days) | 1.4M | ★ 7.4M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.35% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 4.02 | 1.62 |
| Revenue | $2,488,652,000.00 | ★ $37,184,400,000.00 |
| Revenue This Year | $10.79 | $4.88 |
| Revenue Next Year | $10.47 | $5.15 |
| P/E Ratio | $117.29 | ★ $63.80 |
| Revenue Growth | ★ 46.20 | 2.79 |
| 52 Week Low | $362.50 | $77.99 |
| 52 Week High | $533.67 | $109.23 |
| Indicator | VRTX | SBUX |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 52.59 |
| Support Level | $467.30 | $101.65 |
| Resistance Level | $488.71 | $109.06 |
| Average True Range (ATR) | 12.67 | 3.03 |
| MACD | -1.84 | -0.16 |
| Stochastic Oscillator | 46.71 | 40.24 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.